South Korea-based DAAN Biotherapeutics has entered a licensing agreement with GC Cell, granting the latter exclusive rights ...

Researchers in South Korea have proposed a novel cancer immunotherapy approach that could complement existing CAR-T (Chimeric ...

The specificity of T cell recognition is determined by the variable (V) domain of the T cell receptor (TCR ... our efforts on solving the crystal structure of a mouse TCR in complex with an ...

The AERIAL trial will assess LEU011, which has MHRA Innovation Passport status, for solid tumors, a challenging area compared ...

In part 4 of an interview with The American Journal of Managed Care®, Frederick L. Locke, MD, provides insight on the design ...

FDA has cleared an investigational new drug (IND) application to study switchable chimeric antigen receptor T cell (sCAR-T) therapy (CLBR001 + SWI019) in patients with autoimmune conditions. Patient ...

A team of researchers from Barcelona has developed a new material that could make one of the most promising cancer treatments ...

The CAR T-cell therapy KYV-101 is safe, and showed preliminary signs of efficacy in patients with progressive forms of MS in ...

On the other hand, CAR-T cells express high levels of TIM-3, a receptor that normally interacts with galectin-9 to suppress immune activity. The tumor seems to use this interaction to “turn off ...

To date, the Food and Drug Administration (FDA) has approved seven chimeric antigen receptor-T (CAR-T) cell therapies and seven bispecific T-cell engagers (BiTEs) across a variety of hematologic ...

Chimeric antigen receptor (CAR) T-cell therapy has transformed the treatment of refractory or relapsed leukemia and hematologic malignancies, particularly over the past decade. Despite its ...

On the other hand, CAR T cells express high levels of TIM-3, a receptor that normally interacts with galectin-9 to suppress immune activity. The tumor seems to use this interaction to "turn off ...